Interferon signature in patients with STAT1 gain-of-function mutation is epigenetically determined.


Journal

European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201

Informations de publication

Date de publication:
05 2019
Historique:
received: 05 10 2018
revised: 15 01 2019
accepted: 22 02 2019
pubmed: 26 2 2019
medline: 27 5 2020
entrez: 26 2 2019
Statut: ppublish

Résumé

STAT1 gain-of-function (GOF) variants lead to defective Th17 cell development and chronic mucocutaneous candidiasis (CMC), but frequently also to autoimmunity. Stimulation of cells with STAT1 inducing cytokines like interferons (IFN) result in hyperphosphorylation and delayed dephosphorylation of GOF STAT1. However, the mechanism how the delayed dephosphorylation exactly causes the increased expression of STAT1-dependent genes, and how the intracellular signal transduction from cytokine receptors is affected, remains unknown. In this study we show that the circulating levels of IFN-α were not persistently elevated in STAT1 GOF patients. Nevertheless, the expression of interferon signature genes was evident even in the patient with low or undetectable serum IFN-α levels. Chromatin immunoprecipitation (ChIP) experiments revealed that the active chromatin mark trimethylation of lysine 4 of histone 3 (H3K4me3), was significantly enriched in areas associated with interferon-stimulated genes in STAT1 GOF cells in comparison to cells from healthy donors. This suggests that the chromatin binding of GOF STAT1 variant promotes epigenetic changes compatible with higher gene expression and elevated reactivity to type I interferons, and possibly predisposes for interferon-related autoimmunity. The results also suggest that epigenetic rewiring may be responsible for treatment failure of Janus kinase 1/2 (JAK1/2) inhibitors in certain patients.

Identifiants

pubmed: 30801692
doi: 10.1002/eji.201847955
doi:

Substances chimiques

STAT1 Transcription Factor 0
STAT1 protein, human 0
STAT3 Transcription Factor 0
STAT3 protein, human 0
Interferons 9008-11-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

790-800

Informations de copyright

© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Auteurs

Epp Kaleviste (E)

Department of Biomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.

Mario Saare (M)

Department of Biomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.

Timothy Ronan Leahy (TR)

Department of Paediatric Immunology and Infectious Diseases, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland.

Vincent Bondet (V)

Immunobiology of Dendritic Cells Unit, Inserm U1223, Institut Pasteur, Paris, France.

Darragh Duffy (D)

Immunobiology of Dendritic Cells Unit, Inserm U1223, Institut Pasteur, Paris, France.

Trine H Mogensen (TH)

Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Sofie E Jørgensen (SE)

Department of Biomedicine, Aarhus University, Aarhus, Denmark.

Helke Nurm (H)

Department of emergency care and acute infections, Tallinn Children's Hospital, Tallinn, Estonia.

Winnie Ip (W)

Great Ormond Street Hospital & UCL Great Ormond Street Institute of Child Health, London, United Kingdom.

E Graham Davies (EG)

Great Ormond Street Hospital & UCL Great Ormond Street Institute of Child Health, London, United Kingdom.

Sascha Sauer (S)

Otto Warburg Laboratory, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Laboratory of Functional Genomics, Nutrigenomics and Systems Biology, Max-Delbrück-Center for Molecular Medicine (BIMSB/BIH), Berlin, Germany.

Ann-Christine Syvänen (AC)

Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

Lili Milani (L)

Estonian Genome Center, University of Tartu, Tartu, Estonia.

Pärt Peterson (P)

Department of Biomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.

Kai Kisand (K)

Department of Biomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH